4.6 Review

Clinical Manifestations and Pathogenesis of Acute Necrotizing Encephalopathy: The Interface Between Systemic Infection and Neurologic Injury

Journal

FRONTIERS IN NEUROLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2021.628811

Keywords

encephalitis; COVID-19; influenza; ANE; RanBP2; nucleocytoplasmic transport

Funding

  1. NIH [R21NS121462]

Ask authors/readers for more resources

Acute necrotizing encephalopathy (ANE) is a severe neurological condition that can occur following systemic infections such as influenza and SARS-CoV-2. The disease is characterized by rapid changes in consciousness, neurological deficits, and seizures. Neuroimaging reveals bilateral deep gray matter lesions, often involving the thalami, with evidence of necrosis and/or hemorrhage. Differential diagnosis includes viral infection of the central nervous system, as well as metabolic and mitochondrial disorders. The prognosis of ANE is generally poor, especially in cases involving the brainstem. Current management focuses on modulating immune responses to mitigate neurological injury.
Acute necrotizing encephalopathy (ANE) is a devastating neurologic condition that can arise following a variety of systemic infections, including influenza and SARS-CoV-2. Affected individuals typically present with rapid changes in consciousness, focal neurological deficits, and seizures. Neuroimaging reveals symmetric, bilateral deep gray matter lesions, often involving the thalami, with evidence of necrosis and/or hemorrhage. The clinical and radiologic picture must be distinguished from direct infection of the central nervous system by some viruses, and from metabolic and mitochondrial disorders. Outcomes following ANE are poor overall and worse in those with brainstem involvement. Specific management is often directed toward modulating immune responses given the potential role of systemic inflammation and cytokine storm in potentiating neurologic injury in ANE, though benefits of such approaches remain unclear. The finding that many patients have mutations in the nucleoporin gene RANBP2, which encodes a multifunctional protein that plays a key role in nucleocytoplasmic transport, may allow for the development of disease models that provide insights into pathogenic mechanisms and novel therapeutic approaches.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available